Dicer 的棘手角色：对 RNAi 治疗的影响。
The dicey role of Dicer: implications for RNAi therapy.
机构信息
Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston, Texas.
出版信息
Cancer Res. 2010 Apr 1;70(7):2571-4. doi: 10.1158/0008-5472.CAN-09-2536. Epub 2010 Feb 23.
Abstract
The dynamic properties of RNA interference (RNAi) in cancer biology have led investigators to pursue with significant interest its role in tumorigenesis and cancer therapy. We recently reported that decreased expression of key RNAi enzymes, Dicer and Drosha, in epithelial ovarian cancers was associated with poor clinical outcome in patients. Dicer expression was also functionally relevant in that targeted silencing was limited with RNAi fragments that require Dicer function compared with those that do not. Together, this and other studies suggest that RNAi machinery expression may affect key pathways in tumorigenesis and cancer biology. Understanding alterations in the functional RNAi machinery is of fundamental importance as we strive to develop novel therapies using RNAi strategies.
摘要
RNA 干扰 (RNAi) 在癌症生物学中的动态特性促使研究人员对其在肿瘤发生和癌症治疗中的作用产生了浓厚的兴趣。我们最近报道称，上皮性卵巢癌中关键 RNAi 酶 Dicer 和 Drosha 的表达降低与患者临床预后不良相关。Dicer 的表达在功能上也是相关的，因为与不需要 Dicer 功能的 RNAi 片段相比，靶向沉默受到限制。这些研究和其他研究表明，RNAi 机制的表达可能会影响肿瘤发生和癌症生物学中的关键途径。了解功能性 RNAi 机制的改变对于我们努力使用 RNAi 策略开发新的治疗方法至关重要。
相似文献
1
The dicey role of Dicer: implications for RNAi therapy.Dicer 的棘手角色：对 RNAi 治疗的影响。
Cancer Res. 2010 Apr 1;70(7):2571-4. doi: 10.1158/0008-5472.CAN-09-2536. Epub 2010 Feb 23.
2
RNase III enzymes and the initiation of gene silencing.核糖核酸酶III类酶与基因沉默的起始
Nat Struct Mol Biol. 2004 Mar;11(3):214-8. doi: 10.1038/nsmb729.
3
Dicer, Drosha, and outcomes in patients with ovarian cancer.Dicer、Drosha与卵巢癌患者的预后
N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785.
4
RNAi in clinical studies.RNAi 在临床研究中的应用。
Curr Med Chem. 2013;20(14):1801-16. doi: 10.2174/09298673113209990118.
5
Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.RNA 干扰在癌症治疗中的应用作为一种抑制基因表达的强大工具。
Mol Biol Rep. 2009 Nov;36(8):2153-63. doi: 10.1007/s11033-008-9429-7. Epub 2009 Jan 1.
6
Functional canonical RNAi in mice expressing a truncated Dicer isoform and long dsRNA.表达截短 Dicer 异构体和长 dsRNA 的小鼠中的功能性经典 RNAi。
EMBO Rep. 2024 Jul;25(7):2896-2913. doi: 10.1038/s44319-024-00148-z. Epub 2024 May 20.
7
Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways.果蝇Dicer-1和Dicer-2在小干扰RNA/微小RNA沉默途径中的不同作用。
Cell. 2004 Apr 2;117(1):69-81. doi: 10.1016/s0092-8674(04)00261-2.
8
Dicer-independent, Ago2-mediated microRNA biogenesis in vertebrates.脊椎动物中非依赖 Dicer、AGO2 介导的 microRNA 生成。
Cell Cycle. 2010 Nov 15;9(22):4455-60. doi: 10.4161/cc.9.22.13958.
9
RNA interference and cancer therapy.RNA 干扰与癌症治疗。
Pharm Res. 2011 Dec;28(12):2983-95. doi: 10.1007/s11095-011-0604-5. Epub 2011 Oct 19.
10
Abrogation of DNA vector-based RNAi during apoptosis in mammalian cells due to caspase-mediated cleavage and inactivation of Dicer-1.在哺乳动物细胞凋亡过程中，由于半胱天冬酶介导的Dicer-1切割和失活，基于DNA载体的RNA干扰被废除。
Cell Death Differ. 2009 Jun;16(6):858-68. doi: 10.1038/cdd.2009.15. Epub 2009 Feb 20.
引用本文的文献
1
Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis.系统给予载有 siRNA 的中性脂质体纳米粒以实现 mTOR 的治疗性沉默可抑制 DMBA 诱导的乳腺肿瘤发生。
Br J Cancer. 2022 Dec;127(12):2207-2219. doi: 10.1038/s41416-022-02011-1. Epub 2022 Oct 19.
2
Analysing miRNA-Target Gene Networks in Inflammatory Bowel Disease and Other Complex Diseases Using Transcriptomic Data.利用转录组数据分析炎症性肠病和其他复杂疾病中的miRNA-靶基因网络
Genes (Basel). 2022 Feb 18;13(2):370. doi: 10.3390/genes13020370.
3
miR-30a attenuates drug sensitivity to 5-FU by modulating cell proliferation possibly by downregulating cyclin E2 in oral squamous cell carcinoma.在口腔鳞状细胞癌中，miR-30a可能通过下调细胞周期蛋白E2来调节细胞增殖，从而减弱对5-氟尿嘧啶的药物敏感性。
Biochem Biophys Rep. 2021 Sep 21;28:101114. doi: 10.1016/j.bbrep.2021.101114. eCollection 2021 Dec.
4
Prognostic molecular biomarkers in endometrial cancer: A review.子宫内膜癌的预后分子生物标志物：综述
J Cancer Res Ther (Manch). 2019 Dec;7(3):17-28. doi: 10.14312/2052-4994.2019-3. Epub 2019 Dec 3.
5
An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance.miRNA细胞摄取机制分析以增强癌症化疗耐药性中的药物递送及疗效
Noncoding RNA. 2021 Apr 16;7(2):27. doi: 10.3390/ncrna7020027.
6
Recent advances in polymeric drug delivery systems.聚合物药物递送系统的最新进展。
Biomater Res. 2020 Jun 6;24:12. doi: 10.1186/s40824-020-00190-7. eCollection 2020.
7
Using a Lentivirus-Based Inducible RNAi Vector to Silence a Gene.使用基于慢病毒的可诱导RNA干扰载体沉默基因。
Methods Mol Biol. 2020;2102:195-210. doi: 10.1007/978-1-0716-0223-2_10.
8
Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer.外泌体miRNA-107诱导胃癌中髓源性抑制细胞扩增。
Cancer Manag Res. 2019 May 6;11:4023-4040. doi: 10.2147/CMAR.S198886. eCollection 2019.
9
Association of MicroRNA Biogenesis Genes Polymorphisms with Ischemic Stroke Susceptibility and Post-Stroke Mortality.微小RNA生物合成基因多态性与缺血性中风易感性及中风后死亡率的关联
J Stroke. 2018 Jan;20(1):110-121. doi: 10.5853/jos.2017.02586. Epub 2018 Jan 31.
10
miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence.不依赖微小RNA的丙型肝炎病毒变体表明存在维持对miR-122依赖的强大进化压力。
PLoS Pathog. 2017 Oct 30;13(10):e1006694. doi: 10.1371/journal.ppat.1006694. eCollection 2017 Oct.
本文引用的文献
1
Causes and consequences of microRNA dysregulation in cancer.癌症中微小RNA失调的原因及后果。
Nat Rev Genet. 2009 Oct;10(10):704-14. doi: 10.1038/nrg2634.
2
Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer.微小 RNA 在包括卵巢癌在内的各种疾病的诊断和治疗中的新作用。
J Ovarian Res. 2009 Aug 27;2(1):11. doi: 10.1186/1757-2215-2-11.
3
Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps.AGO蛋白结合位点的高通量测序解析微小RNA-信使核糖核酸相互作用图谱。
Nature. 2009 Jul 23;460(7254):479-86. doi: 10.1038/nature08170. Epub 2009 Jun 17.
4
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.治疗性微小RNA递送可抑制小鼠肝癌模型中的肿瘤发生。
Cell. 2009 Jun 12;137(6):1005-17. doi: 10.1016/j.cell.2009.04.021.
5
RNA interference: emerging diagnostics and therapeutics tool.RNA干扰：新兴的诊断与治疗工具。
Biochem Biophys Res Commun. 2009 Aug 21;386(2):273-7. doi: 10.1016/j.bbrc.2009.06.018. Epub 2009 Jun 10.
6
MicroRNAs and cancer--new paradigms in molecular oncology.微小RNA与癌症——分子肿瘤学的新范式
Curr Opin Cell Biol. 2009 Jun;21(3):470-9. doi: 10.1016/j.ceb.2009.03.002. Epub 2009 May 4.
7
Dicer, Drosha, and outcomes in patients with ovarian cancer.Dicer、Drosha与卵巢癌患者的预后
N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785.
8
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.通过全身递送脂质体包裹的蛋白酶激活受体-1小干扰RNA靶向黑色素瘤生长和转移
Cancer Res. 2008 Nov 1;68(21):9078-86. doi: 10.1158/0008-5472.CAN-08-2397.
9
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.miR-15a-miR-16-1簇通过靶向多种致癌活性来控制前列腺癌。
Nat Med. 2008 Nov;14(11):1271-7. doi: 10.1038/nm.1880. Epub 2008 Oct 19.
10
microRNAs and cancer: an overview.微小RNA与癌症：综述
Cell Cycle. 2008 Aug 15;7(16):2485-92. doi: 10.4161/cc.7.16.6453. Epub 2008 Aug 17.
Zotero 插件